Evaluation of the effects of multiple doses of olpasiran on baseline Lp(a), and treatment safety and tolerability

(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.